PAVmed Inc. (PAVM)

Market Cap	15.78M
Revenue (ttm)	2.45M
Net Income (ttm)	-66.27M
Shares Out	9.17M
EPS (ttm)	-9.16
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,299
Open	1.790
Previous Close	1.740
Day's Range	1.725 - 1.860
52-Week Range	1.600 - 9.000
Beta	0.83
Analysts	Hold
Price Target	8.61 (+399.13%)
Earnings Date	May 14, 2024

About PAVM

PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, incl...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Apr 28, 2016
• Employees: 107
• Stock Exchange: NASDAQ
• Ticker Symbol: PAVM

Financial Performance

In 2023, PAVmed's revenue was $2.45 million, an increase of 550.40% compared to the previous year's $377,000. Losses were -$66.27 million, -25.76% less than in 2022.

Analyst Forecast

According to one analyst, the rating for PAVM stock is "Hold" and the 12-month stock price forecast is $8.61.

Price Target

$8.61

(399.13% upside)

Analyst Consensus: Hold